Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
HemoGenyx Pharmaceuticals Plc (GB:HEMO)
LSE:HEMO
HemoGenyx Pharmaceuticals Plc (HEMO) Share Price & Analysis
10 Followers
HEMO Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1.10p - 7.13p
Previous Close1.6p
Volume3.32M
Average Volume (3M)16.58M
Market Cap
£21.46M
Enterprise Value22.31M
Total Cash (Recent Filing)£2.53M
Total Debt (Recent Filing)£3.42M
Price to Earnings (P/E)-2.5
Beta0.57
Next Earnings
Apr 29, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,141,999,321
10 Day Avg. Volume3,053,276
30 Day Avg. Volume16,579,444
Standard Deviation0.98
R-Squared0.02
Alpha0.12
Financial Highlights & Ratios
Price to Book (P/B)5.67
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
HemoGenyx Pharmaceuticals Plc News
PremiumCompany Announcements
Hemogenyx Advances Clinical Trials and Secures FundingOptions Prices
Currently, No data available
---
Ownership Overview
9.88%
Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
90.12% Public Companies and
Individual Investors
HEMO FAQ
What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?
HemoGenyx Pharmaceuticals Plc lowest share price was 1.10p and its highest was 7.13p in the past 12 months.
What is HemoGenyx Pharmaceuticals Plc’s market cap?
Currently, no data Available
When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?
HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Apr 29, 2024 which is in 4 days.
How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?
HemoGenyx Pharmaceuticals Plc released its earnings results on Sep 28, 2023. The company reported -0.004p earnings per share for the quarter, missing the consensus estimate of N/A by -0.004p.
Is HemoGenyx Pharmaceuticals Plc overvalued?
According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued.
Does HemoGenyx Pharmaceuticals Plc pay dividends?
HemoGenyx Pharmaceuticals Plc does not currently pay dividends.
What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?
HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?
HemoGenyx Pharmaceuticals Plc has 1,341,816,000 shares outstanding.
What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?
HemoGenyx Pharmaceuticals Plc reported an EPS of -0.004p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.638%.
Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in GB:HEMO
---
HemoGenyx Pharmaceuticals Plc Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Company Description
HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals PLC and its subsidiary is a preclinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy.
---
Technical Analysis
---